INmune Bio: Imminent Phase 2 Alzheimer's Readout Of Unique Asset Presents Interesting Speculative Opportunity
2025-06-16 11:29:13 ET
Thesis
INmune Bio (INMB) is a high risk/reward speculative mid-stage biotech ahead of its imminent Phase 2 Alzheimer’s data readout slated to be released this week or next. The company’s lead asset, XPro1595, brings a highly unique mechanism of action as a “selective” TNF-alpha inhibitor, which we believe along with extensive preclinical, mechanistic, and encouraging (though very incomplete) Phase 1b data, make the Phase 2 readout perhaps the most intriguing mid-stage Alzheimer’s readout opportunity that we have seen.
XPro1595 selectively targets and inhibits soluble TNF (sTNF), which has been widely demonstrated to be the inflammation- and damage-inducing form of TNF-alpha, while sparing the other form of TNF-alpha, called transmembrane TNF (tmTNF), which, interestingly, has been widely demonstrated to be anti-inflammatory and reparative in many biological contexts....
Read the full article on Seeking Alpha
For further details see:
INmune Bio: Imminent Phase 2 Alzheimer's Readout Of Unique Asset Presents Interesting Speculative Opportunity
NASDAQ: INMB
INMB Trading
-5.44% G/L:
$1.565 Last:
646,918 Volume:
$1.66 Open:
